Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-271].

Durgam, Suresh; Earley, Willie; Li, Rui; Li, Dayong; Lu, Kaifeng; Laszlovszky, István; Wolfgang Fleischhacker, W; Nasrallah, Henry A

Durgam, Suresh; Earley, Willie; Li, Rui; Li, Dayong; Lu, Kaifeng; Laszlovszky, István; Wolfgang Fleischhacker, W; Nasrallah, Henry A.

Afiliación

Durgam S; Allergan, Inc., Jersey City, NJ, USA. Electronic address: suresh.durgam@allergan.com.
Earley W; Allergan, Inc., Jersey City, NJ, USA.
Li R; Allergan, Inc., Jersey City, NJ, USA.
Li D; Allergan, Inc., Jersey City, NJ, USA.
Lu K; Allergan, Inc., Jersey City, NJ, USA.
Laszlovszky I; Gedeon Richter Plc, Budapest, Hungary.
Wolfgang Fleischhacker W; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria.
Nasrallah HA; Saint Louis University, St. Louis, MO, USA.

Schizophr Res ; 192: 493, 2018 02.

Article en En | MEDLINE | ID: mdl-28427929

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Schizophr Res Asunto de la revista: PSIQUIATRIA Año: 2018 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google